Medroxyprogesterone acetate concentrations among HIV-infected depot-medroxyprogesterone acetate users receiving antiretroviral therapy in Lilongwe, Malawi
Zia, Y.; Tang, J.H.; Chinula, L.; Tegha, G.; Stanczyk, F.Z.; Kourtis, A.P.
Contraception 100(5): 402-405
2019
ISSN/ISBN: 1879-0518 PMID: 31374188 DOI: 10.1016/j.contraception.2019.07.144Document Number: 424160
To compare medroxyprogesterone acetate (MPA) concentrations between HIV-positive women on antiretroviral therapy (ART) and HIV-negative women initiating depot medroxyprogesterone (DMPA) injectable. Secondary analysis of 28 HIV-positive women on non-nucleoside reverse transcriptase inhibitor-containing ART regimens and 10 HIV-negative women randomized to initiate DMPA in a clinical trial of progestin contraception in Malawi. MPA concentrations were significantly lower among HIV-positive women on ART, compared with HIV-negative women, at week 4 and week 13 (p=.03 for both), but not at day 3 or week 26 post-DMPA initiation. Antiretroviral medications may affect MPA metabolism in HIV-positive African women.